Identification of FKBP10 prognostic value in lung adenocarcinoma patients with surgical resection of brain metastases: A retrospective single-institution cohort study

• Published in: Clinics (São Paulo, Brazil) Vol. 78; p. 100212
• Main Authors: Liu, Zhi-Dan, Wang, Song-Quan, Li, Sai, He, Jie, Wang, Shao-Hua, Cai, Hong-Qing, Wan, Jing-Hai
• Format: Journal Article
• Language: English
• Published: United States Elsevier España, S.L.U 01.01.2023; Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo; Faculdade de Medicina / USP
• Subjects: Adenocarcinoma of Lung - pathology; Brain metastases; Brain Neoplasms - secondary; Brain Neoplasms - surgery; Cohort Studies; FKBP10; Humans; Lung adenocarcinoma; Lung Neoplasms - pathology; MEDICINE, GENERAL & INTERNAL; Original; Prognosis; Retrospective Studies; Tacrolimus Binding Proteins; FKBP10; Brain metastases; Lung adenocarcinoma
• ISSN: 1807-5932; 1980-5322; 1980-5322
• DOI: 10.1016/j.clinsp.2023.100212

•FKBP10 proteins are highly expressed in lung adenocarcinoma, including brain metastasis tissue.•FKBP10 is a valuable prognostic indicator for lung adenocarcinoma.•FKBP10 is a potential clinical biomarker for lung adenocarcinoma. To explore the expression levels and clinical value of FKBP10 in lung adenocarcinoma brain metastases. A retrospective single-institution cohort study. The perioperative records of 71 patients with lung adenocarcinoma brain metastases who underwent surgical resection at the authors’ institution between November 2012 and June 2019 were retrospectively analyzed. The authors evaluated FKBP10 expression levels using immunohistochemistry in tissue arrays of these patients. Kaplan-Meier survival curves were constructed, and a Cox proportional hazards regression model was used to identify independent prognostic biomarkers. A public database was used to detect FKBP10 expression and its clinical value in primary lung adenocarcinoma. The authors found that the FKBP10 protein was selectively expressed in lung adenocarcinoma brain metastases. Survival analysis showed that FKBP10 expression (p = 0.02, HR = 2.472, 95% CI [1.156, 5.289]), target therapy (p < 0.01, HR = 0.186, 95% CI [0.073, 0.477]), and radiotherapy (p = 0.006, HR = 0.330, 95% CI [0.149, 0.731]) were independent prognostic factors for survival in lung adenocarcinoma patients with brain metastases. The authors also detected FKBP10 expression in primary lung adenocarcinoma using a public database, found that FKBP10 is also selectively expressed in primary lung adenocarcinoma, and affects the overall survival and disease-free survival of patients. The number of enrolled patients was relatively small and patients’ treatment options varied. A combination of surgical resection, adjuvant radiotherapy, and precise target therapy may benefit the survival of selected patients with lung adenocarcinoma brain metastases. FKBP10 is a novel biomarker for lung adenocarcinoma brain metastases, which is closely associated with survival time and may serve as a potential therapeutic target.